Previous studies show that Bcr-Abl inhibitor Dasatinib could also inhibit SRC family kinases, and their inhibitions may cause adverse events such as skin eruption, fluid retention, skin or hair depigmentation, and pulmonary arterial hypertension (PAH)21,26. Here, SRC is linked to pulmonary arterial hypertension.